Abstract
The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Current Respiratory Medicine Reviews
Title: Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease
Volume: 5 Issue: 3
Author(s): Nickolaos G. Koulouris, Antonia Koutsoukou and Edgardo D'Angelo
Affiliation:
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Abstract: The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Export Options
About this article
Cite this article as:
Koulouris G. Nickolaos, Koutsoukou Antonia and D'Angelo Edgardo, Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease, Current Respiratory Medicine Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339809788922379
DOI https://dx.doi.org/10.2174/157339809788922379 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook
Current Genomics Integrin Antagonists: A Special Emphasis on Structural Requirements of N-benzoyl-L-biphenylalanines as α4β7 and α4β1 Antagonists
Current Signal Transduction Therapy Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment
Recent Patents on Drug Delivery & Formulation Pidotimod and Immunological Activation in Individuals Infected with HIV
Current HIV Research Cytokine-Induced Inflammatory Liver Injuries
Current Molecular Medicine Isoforms of Vitamin E Differentially Regulate Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story
Current Pharmaceutical Design Effect of Alpha-1-Acid Glycoprotein Binding on Pharmacokinetics and Pharmacodynamics
Current Drug Metabolism Investigating the Associations between Mediterranean Diet, Physical Activity and Living Environment with Childhood Asthma using Path Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Heme Oxygenase-1 in Lung Disease
Current Drug Targets Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews Role of Metallothionein in Inflammatory Lung Diseases
Current Respiratory Medicine Reviews Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Bronchial Asthma, Chronic Obstructive Pulmonary Disease and NF-κB
Current Medicinal Chemistry NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy